Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Sep;62(3):415–419. doi: 10.1038/bjc.1990.309

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.

K Nishio 1, Y Sugimoto 1, K Nakagawa 1, S Niimi 1, Y Fujiwara 1, M Bungo 1, K Kasahara 1, H Fujiki 1, N Saijo 1
PMCID: PMC1971464  PMID: 2206949

Abstract

The growth inhibitory effect of tumour promoters on human leukaemia and lung cancer cell lines was examined using the [3-(4,5 dimethylthiazol)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. The four cell lines used were the K562 human leukaemia cell line, its adriamycin (ADM)-resistant subline (K562/ADM), which shows the mdr phenotype, PC-9 (a human lung adenocarcinoma cell line) and its cisplatin (CDDP)-resistant subline (PC-9/CDDP), which does not show the mdr phenotype. Phorbol 12-tetradecanoate-13-acetate (TPA) and the TPA-type tumour promoters, aplysiatoxin and debromoaplysiatoxin, inhibited the growth of the two parental cell lines, K562 and PC-9. The non-TPA-type tumour promoter, okadaic acid, also inhibited the growth of the two parental cell lines in a dose-dependent manner. TPA-type and okadaic acid inhibited the growth of K562/ADM more weakly than that of K562, and showed no growth inhibition in PC-9/CDDP. Anhydrodebromoaplysiatoxin, an inactive derivative of the TPA-type tumour promoter, could suppress the growth of K562 and K562/ADM only at high concentration (more than 50 pM) and it showed similar growth inhibitory effects on the two cell lines. Okadaic acid tetramethyl ether, the inactive form of the non-TPA-type tumour promoter did not inhibit the growth of any of the cell lines. The growth inhibitory effect of these compounds was well correlated with their tumour-promoting activity. A study of the accumulation of okadaic acid revealed that the amount of 3H-okadaic acid in K562/ADM and PC-9/CDDP was similar to that in their parental cells indicating that cross-resistance to this tumour promoter in the drug-resistant cell lines is not due to a difference in the amount of drug accumulated in sensitive and resistant cells. These results suggest the presence of another common mechanism for resistance to ADM and CDDP as well as to TPA- or non-TPA-type tumour promoters.

Full text

PDF
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bungo M., Fujiwara Y., Kasahara K., Nakagawa K., Ohe Y., Sasaki Y., Irino S., Saijo N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 1990 May 1;50(9):2549–2553. [PubMed] [Google Scholar]
  2. Cowan K. H., Goldsmith M. E., Levine R. M., Aitken S. C., Douglass E., Clendeninn N., Nienhuis A. W., Lippman M. E. Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem. 1982 Dec 25;257(24):15079–15086. [PubMed] [Google Scholar]
  3. Ferguson P. J., Cheng Y. C. Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 1987 Jan 15;47(2):433–441. [PubMed] [Google Scholar]
  4. Fine R. L., Patel J., Chabner B. A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci U S A. 1988 Jan;85(2):582–586. doi: 10.1073/pnas.85.2.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fojo A., Akiyama S., Gottesman M. M., Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985 Jul;45(7):3002–3007. [PubMed] [Google Scholar]
  6. Fujiki H., Suganuma M., Matsukura N., Sugimura T., Takayama S. Teleocidin from Streptomyces is a potent promoter of mouse skin carcinogenesis. Carcinogenesis. 1982;3(8):895–898. doi: 10.1093/carcin/3.8.895. [DOI] [PubMed] [Google Scholar]
  7. Fujiki H., Sugimura T. New classes of tumor promoters: teleocidin, aplysiatoxin, and palytoxin. Adv Cancer Res. 1987;49:223–264. doi: 10.1016/s0065-230x(08)60799-x. [DOI] [PubMed] [Google Scholar]
  8. Hamada H., Hagiwara K., Nakajima T., Tsuruo T. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 1987 Jun 1;47(11):2860–2865. [PubMed] [Google Scholar]
  9. Hong W. S., Saijo N., Sasaki Y., Minato K., Nakano H., Nakagawa K., Fujiwara Y., Nomura K., Twentyman P. R. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer. 1988 Mar 15;41(3):462–467. doi: 10.1002/ijc.2910410325. [DOI] [PubMed] [Google Scholar]
  10. Kartner N., Riordan J. R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983 Sep 23;221(4617):1285–1288. doi: 10.1126/science.6137059. [DOI] [PubMed] [Google Scholar]
  11. Koeffler H. P., Bar-Eli M., Territo M. C. Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation. Cancer Res. 1981 Mar;41(3):919–926. [PubMed] [Google Scholar]
  12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  13. Nakagawa K., Yokota J., Wada M., Sasaki Y., Fujiwara Y., Sakai M., Muramatsu M., Terasaki T., Tsunokawa Y., Terada M. Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J Cancer Res. 1988 Mar;79(3):301–304. doi: 10.1111/j.1349-7006.1988.tb01590.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sassa T., Richter W. W., Uda N., Suganuma M., Suguri H., Yoshizawa S., Hirota M., Fujiki H. Apparent "activation" of protein kinases by okadaic acid class tumor promoters. Biochem Biophys Res Commun. 1989 Mar 31;159(3):939–944. doi: 10.1016/0006-291x(89)92199-2. [DOI] [PubMed] [Google Scholar]
  15. Suganuma M., Suttajit M., Suguri H., Ojika M., Yamada K., Fujiki H. Specific binding of okadaic acid, a new tumor promoter in mouse skin. FEBS Lett. 1989 Jul 3;250(2):615–618. doi: 10.1016/0014-5793(89)80807-5. [DOI] [PubMed] [Google Scholar]
  16. Tsuruo T., Iida-Saito H., Kawabata H., Oh-hara T., Hamada H., Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res. 1986 Jul;77(7):682–692. [PubMed] [Google Scholar]
  17. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 1983 May;43(5):2267–2272. [PubMed] [Google Scholar]
  18. Ueda K., Cornwell M. M., Gottesman M. M., Pastan I., Roninson I. B., Ling V., Riordan J. R. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun. 1986 Dec 30;141(3):956–962. doi: 10.1016/s0006-291x(86)80136-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES